SCHEMBL22843445

SCHEMBL22843445

CCN(CP)S(=O)(=O)c1ccc(Nc2ccc(C(F)(F)F)cn2)c(-c2cn(C)cn2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TEAD1 P28347 3/20 0.54
▸ YAP1 P46937 1/20 0.54
▸ KDM4E B2RXH2 3/20 0.38
▸ LMNA P02545 3/20 0.38
▸ GAA P10253 3/20 0.38
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ HTT P42858 2/20 0.38
▸ NPSR1 Q6W5P4 2/20 0.38
▸ MAPT P10636 4/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ TDP1 Q9NUW8 1/20 0.36
▸ TLR2 O60603 1/20 0.35
▸ TLR1 Q15399 1/20 0.35
▸ CCNK O75909 1/20 0.35
▸ CCNA2 P20248 1/20 0.35
▸ CDK2 P24941 1/20 0.35
▸ CDK12 Q9NYV4 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ PTGDR2 Q9Y5Y4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22843430 0.90 TEAD1 (0.54) TEAD1YAP1KDM4ELMNAGAA
SCHEMBL22843441 0.88 TEAD1 (0.51) TEAD1YAP1KDM4ELMNAGAA
SCHEMBL22717994 0.86 TEAD1 (0.48) TEAD1YAP1KDM4ELMNAGAA
SCHEMBL29438911 0.86 TEAD1 (0.48) TEAD1YAP1KDM4ELMNAGAA
SCHEMBL29438868 0.84 TEAD1 (0.62) TEAD1YAP1KDM4ELMNAHTT
SCHEMBL22718325 0.84 TEAD1 (0.62) TEAD1YAP1KDM4ELMNAHTT
SCHEMBL24501728 0.84 TEAD1 (0.61) TEAD1YAP1KDM4EGAAMAPT
SCHEMBL24501068 0.84 TEAD1 (0.61) TEAD1YAP1KDM4EGAAMAPT
SCHEMBL22843427 0.84 KDM4E (0.41) TEAD1KDM4ELMNAGAASMN1; SMN2
SCHEMBL22718190 0.83 TEAD1 (0.77) TEAD1YAP1MAPTTLR2TLR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11760728-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2023-09-19 — — US disclosed
US-11274082-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-03-15 — — US disclosed
US-20200407327-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2020-12-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11274082-B2 Tead inhibitors and uses thereof TEAD2, TEAD3, TEAD4 TEAD1 4/4885YAP1 111/4885KDM4E 972/4885
US-11760728-B2 Tead inhibitors and uses thereof TEAD2, TEAD3, TEAD4 TEAD1 4/4885YAP1 111/4885KDM4E 972/4885
US-20200407327-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 TEAD1 4/4885YAP1 111/4885KDM4E 972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback